Heart scans to look for radiation damage in people with locally advanced lung cancer
Uses heart imaging to check for heart damage after lung cancer radiation and chemotherapy.
Plain-language title generated from the registry record
Registry title: Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Key facts
- Where
- Indianapolis, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Indiana University
- Trial code
- NCT07761910
- Record updated
- 10 November 2026
- Original description
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).Read full original descriptionShow less
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
Inclusion: Age ≥ 18 at time of consent; Ability to provide written informed consent and HIPAA authorization; Stage III NSCLC per AJCC 8th edition guideline, confirmed by pathological diagnosis and PET/CT; To receive standard definitive concurrent chemoradiation therapy per NCCN guidelines; Tumor estimated to be within 2cm of heart contour or anticipated MHD>10Gy per treating physician.
Exclusion: Patients treated with stereotactic body radiotherapy (SBRT); Prior thoracic radiotherapy; Exclusion for Coronary computed tomography angiography (CCTA); Patients on radioactive iodine therapy; Exclusion for 18F-Flurpiridaz PET/CT Test; Second-degree AV block, third-degree AV block, and sinus node disease (such as sick sinus syndrome or symptomatic bradycardia) without a functioning pacemaker; Note: Resting 12-lead EKG will be ordered at the time of enrollment to be performed prior to PET/CT stress test; History of a severe anaphylactic reaction to iodinated contrast; Renal insufficiency (defined as estimated CrCl less than 30 mL/min); Patients with bronchospastic diseases including asthma and chronic obstructive pulmonary disease (COPD) who have an acute exacerbation or active wheezing (a high-pitched, musical, adventitious lung sound produced by airflow through the narrowed airways) on the day of PET CT exam; Inability to hold breath for more than 5 seconds; Patients who are hypotensive (systolic blood pressure less than 90 mm Hg) on the day of the PET/CT scan.